<DOC>
	<DOCNO>NCT02480348</DOCNO>
	<brief_summary>The purpose trial evaluate clinical safety efficacy Polymer-Free Drug-Eluting coronary stent system treatment de novo lesion native coronary artery reference vessel diameter ( RVD ) allow use stent 2.25 3.50 mm diameter .</brief_summary>
	<brief_title>Medtronic RevElution Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Must acceptable candidate percutaneous coronary intervention , stenting , &amp; emergent coronary artery bypass graft ( CABG ) surgery Must evidence ischemic heart disease Must require treatment either ) single target lesion amenable treatment 2.25 mm 3.50 mm stent OR b ) two target lesion locate separate target vessel , least one target lesion amenable treatment 2.25 mm 3.50 mm mm study stent Target lesion ( ) must de novo lesion ( ) native coronary artery ( y ) Known hypersensitivity contraindication aspirin , heparin bivalirudin , thienopyridines , cobalt , nickel , platinum , iridium , chromium , molybdenum , polymer coating ( e.g . BioLinx ) sensitivity contrast medium , adequately premedicated History allergic reaction significant sensitivity drug zotarolimus , rapamycin , tacrolimus , everolimus , analogue derivative History stroke transient ischemic attack ( TIA ) within prior 6 month Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month History bleed diathesis coagulopathy refuse blood transfusion Concurrent medical condition life expectancy le 5 year Currently participate investigational drug another device trial complete primary endpoint Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>